Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Thiopurine Therapy in Ulcerative Colitis
NCT02910245Phase 3Unknown
- Sponsor
- University of Amsterdam
- Start
- Nov 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Mercaptopurine with Placebo (2 arms). Primary endpoint: Clinical and endoscopic remission at 52 weeks. Status: unknown.
02
Drugs
mercaptopurine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02910245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910245.